ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
다우존스 지수
40,003.59
0.34%
Bitcoin
66,182.25
-1.13%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Biodexa Pharmaceuticals PLC (BDRX)

  7. Biodexa Pharmaceuticals PLC (BDRX) 뉴스

BDRX

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals PLC
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:BDRX
일자시간출처헤드라인심볼기업
2024/05/1516:57GlobeNewswire Inc.Posting of Annual Report & Notice of AGM - Total Voting RightsNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2024/05/0100:51GlobeNewswire Inc.Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual MeetingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2024/04/2621:30GlobeNewswire Inc.Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)NASDAQ:BDRXBiodexa Pharmaceuticals PLC
2024/04/1921:00GlobeNewswire Inc.Preliminary Results for the Year Ended 31 December 2023NASDAQ:BDRXBiodexa Pharmaceuticals PLC
2024/02/2322:30GlobeNewswire Inc.Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D UpdateNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2024/02/1322:15AllPennyStocks.comBiotech Shares Bid Up Premarket Following 9.9% Institutional Stake DisclosureNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2024/02/0822:30GlobeNewswire Inc.Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma PatientsNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2024/02/0722:30GlobeNewswire Inc.Biodexa Announces Allowance of U.S. Patent Covering TolimidoneNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2024/01/2222:30GlobeNewswire Inc.Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024NASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/12/2918:05GlobeNewswire Inc.Biodexa Appoints Ann Merchant to the Board of DirectorsNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/12/2206:00GlobeNewswire Inc.Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment OptionNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/12/1922:42GlobeNewswire Inc.Biodexa Announces Pricing of $5.2 Million Underwritten Public OfferingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/11/2723:00GlobeNewswire Inc.Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 DiabetesNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/10/0321:30GlobeNewswire Inc.Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent GlioblastomaNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/09/3005:30GlobeNewswire Inc.Interim results for the six months ended 30 June 2023NASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/09/2121:30GlobeNewswire Inc.Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)NASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/07/2821:00GlobeNewswire Inc.Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials WebsitesNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/07/2420:30GlobeNewswire Inc.Biodexa Regain Compliance with NASDAQ Minimum Bid Price RequirementNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/07/1021:00GlobeNewswire Inc.Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)NASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/07/0705:30GlobeNewswire Inc.Results of Appeal of Delisting DeterminationNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/07/0621:15GlobeNewswire Inc.Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)NASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/06/2305:15GlobeNewswire Inc.ADR Ratio ChangeNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/06/2021:00GlobeNewswire Inc.Appeal of Delisting DeterminationNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/06/1605:05GlobeNewswire Inc.Receipt of NASDAQ Delisting Determination Plans to AppealNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/06/1421:30GlobeNewswire Inc.Results of Annual General Meeting and General MeetingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/05/2705:05GlobeNewswire Inc.Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct OfferingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/05/2421:40GlobeNewswire Inc.Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct OfferingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/05/2305:15GlobeNewswire Inc.Posting of Annual Report & Notice of AGMNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/05/1821:30GlobeNewswire Inc.Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian BiopharmaceuticalsNASDAQ:BDRXBiodexa Pharmaceuticals PLC
2023/04/2905:30GlobeNewswire Inc.Preliminary Results for the Year Ended 31 December 2022NASDAQ:BDRXBiodexa Pharmaceuticals PLC
 검색 관련기사 보기:NASDAQ:BDRX

최근 히스토리

COIN
BTCUSD
Bitcoin
NYSE
DIS
Walt Disney
FX
USDEUR
US Dollar vs Euro
USI
USTECH100
US Tech 100
CCOM
SILVER
SILVER
PM
XAUUSD
Gold vs US Dollar
USOTC
BNPQY
BNP Paribas (QX)
FX
USDJPY
US Dollar vs Yen
AMEX
XLV
Health Care Select Sector
NASDAQ
MSFT
Microsoft
NYSE
XOM
Exxon Mobil
NYSE
BAC
Bank of America
NYSE
JPM
JP Morgan Chase
COIN
ETHUSD
Ethereum
CCOM
US100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유